CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

ColdZyme® mouth sprayWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (12)

Name (Synonyms) Correlation
drug401 Hydroxychloroquine, Doxycycline Wiki 1.00
drug399 Hydroxychloroquine, Clindamycin, Primaquine - high dose. Wiki 1.00
drug430 Interferon-Alpha2B Wiki 1.00
drug400 Hydroxychloroquine, Clindamycin, Primaquine - low dose. Wiki 1.00
drug228 Convalescent Serum Wiki 1.00
drug397 Hydroxychloroquine, Azithromycin Wiki 1.00
drug398 Hydroxychloroquine, Clindamycin Wiki 1.00
drug480 Losartan Wiki 0.38
drug507 Methylprednisolone Wiki 0.35
drug691 Remdesivir Wiki 0.30
drug854 Tocilizumab Wiki 0.25
drug616 Placebo Wiki 0.10

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D003139 Common Cold NIH 0.71

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Evaluation of ColdZyme® Mouth Spray on Prevention and Alleviation of Induced Rhinovirus Upper Respiratory Tract Infection in Healthy Volunteers. A Double-blind, Randomized, Placebo-controlled Study

This study evaluates the performance of ColdZyme® mouth spray on prevention and alleviation of induced rhinovirus upper respiratory tract infection in healthy volunteers. Half of participants will receive ColdZyme® mouth spray while the other half will receive placebo.

NCT02522949 Common Cold Device: ColdZyme® mouth spray Device: Placebo
MeSH:Common Cold

Primary Outcomes

Description: Reduction in viral load in the URT(Upper Respiratory Tract), after challenge with rhinovirus, in relation to placebo

Measure: Reduction in viral load in the URT

Time: 7 days

Secondary Outcomes

Description: Reduction of number of days having a total symptom severity score of 6 or higher using a 5-graded Jackson scale, in relation to placebo.

Measure: Prevention of symptomatic URTI (Upper Respiratory Tract Infection)

Time: 11 days

Description: Asymptomatic URTI will be assessed by quantification of viral load at peak day (day with highest viral load measured by oropharyngeal swab).

Measure: Prevention of asymptomatic URTI.

Time: 11 days

Description: The number of days with cold is defined as the sum of all days with a total score of ≥ 6 according to the modified method of Jackson.

Measure: Fewer days with symptomatic URTI

Time: 11 days

Description: The number of days with asymptomatic URTI is defined as the sum of all days with a viral load significantly different from the baseline.

Measure: Fewer days with asymptomatic URTI.

Time: 11 days

Description: Nasal samples will be analysed for the quantity of IL-6 (Interleukin 6), IL-8 and IFNα (Interferon alpha).

Measure: Lower level of proinflammatory proteins

Time: 11 days

Measure: Lower daily total symptom score

Time: 11 days

Measure: Lower daily score of individual symptoms

Time: 11 days

No related HPO nodes (Using clinical trials)